Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
44
BIIB Quote, Financials, Valuation and Earnings
Last price:
$128.72
Seasonality move
:
6.82%
Day range:
$127.42 - $129.51
52-week range:
$110.04 - $236.48
Dividend yield:
0%
P/E ratio:
12.68x
P/S ratio:
1.91x
P/B ratio:
1.11x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
-42.91%
Market cap:
$18.8B
Revenue:
$9.7B
EPS (TTM):
$10.13
Analysts' Opinion
-
Consensus RatingBiogen has received a consensus rating of Hold. The company's average rating is a Hold based on 14 Buy ratings, 18 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $172.51, Biogen has an estimated upside of 34.29% from its current price of $128.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 10.48% downside risk from its current price of $128.46.
Fair Value
-
According to the consensus of 33 analysts, Biogen has 34.29% upside to fair value with a price target of $172.51 per share.
BIIB vs. S&P 500
-
Over the past 5 trading days, Biogen has underperformed the S&P 500 by -3.49% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biogen has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Biogen reported revenues of $2.4B.
Earnings Growth
-
Biogen earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Biogen reported earnings per share of $1.64.
Enterprise value:
22.5B
EV / Invested capital:
--
Price / LTM sales:
1.91x
EV / EBIT:
11.30x
EV / Revenue:
2.29x
PEG ratio (5yr expected):
0.48x
EV / Free cash flow:
9.81x
Price / Operating cash flow:
8.18x
Enterprise value / EBITDA:
8.33x
Gross Profit (TTM):
$7.4B
Return On Assets:
5.37%
Net Income Margin (TTM):
15.07%
Return On Equity:
9.11%
Return On Invested Capital:
6.55%
Operating Margin:
25.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $10.1B | $9.7B | $9.8B | $2.3B | $2.4B | |
| Gross Profit | $7.9B | $7.3B | $7.4B | $1.7B | $1.8B | |
| Operating Income | $2.8B | $1.9B | $2.3B | $577.5M | $625.2M | |
| EBITDA | $4.5B | $2.1B | $2.7B | $681.5M | $554.4M | |
| Diluted EPS | $21.54 | $8.01 | $10.13 | $2.70 | $1.64 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.7B | $7.9B | $9.8B | $6.8B | $7.6B | |
| Total Assets | $23.9B | $23.6B | $24.6B | $26.6B | $28B | |
| Current Liabilities | $3.2B | $3.9B | $3B | $3.2B | $5.3B | |
| Total Liabilities | $13.2B | $12.4B | $10.8B | $11.4B | $11.1B | |
| Total Equity | $10.7B | $11.2B | $13.8B | $15.2B | $17B | |
| Total Debt | $7.3B | $7.3B | $6.3B | $6.5B | $6.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.7B | $1.6B | $2.6B | $553.2M | $259.3M | |
| Cash From Investing | $1.3B | -$3.2B | -$780.5M | -$66M | -$47.3M | |
| Cash From Financing | -$1.8B | -$246.9M | -$266.9M | -$439.6M | -$23M | |
| Free Cash Flow | $1.4B | $1.3B | $2.3B | $432.3M | $212.2M | |
BIIB
Sector
Market Cap
$18.8B
$34.4M
Price % of 52-Week High
54.32%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-42.91%
-37.36%
Beta (5-Year)
0.141
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$132.03
200-day SMA
Sell
Level
$145.66
Bollinger Bands (100)
Sell
Level
121.07 - 139.19
Chaikin Money Flow
Buy
Level
113.2M
20-day SMA
Sell
Level
$129.47
Relative Strength Index (RSI14)
Sell
Level
46.90
ADX Line
Sell
Level
14.55
Williams %R
Neutral
Level
-67.2884
50-day SMA
Buy
Level
$128.23
MACD (12, 26)
Buy
Level
0.74
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
292.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8221)
Buy
CA Score
(Annual)
Level (0.3672)
Buy
Beneish M-Score
(Annual)
Level (-2.8061)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.0222)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Stock Forecast FAQ
In the current month, BIIB has received 14 Buy ratings 18 Hold ratings, and 1 Sell ratings. The BIIB average analyst price target in the past 3 months is $172.51.
-
Where Will Biogen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biogen share price will rise to $172.51 per share over the next 12 months.
-
What Do Analysts Say About Biogen?
Analysts are divided on their view about Biogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biogen is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is Biogen's Price Target?
The price target for Biogen over the next 1-year time period is forecast to be $172.51 according to 33 Wall Street analysts, 14 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
-
Is BIIB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biogen is a Hold. 18 of 33 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIIB?
You can purchase shares of Biogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biogen shares.
-
What Is The Biogen Share Price Today?
Biogen was last trading at $128.72 per share. This represents the most recent stock quote for Biogen. Yesterday, Biogen closed at $128.46 per share.
-
How To Buy Biogen Stock Online?
In order to purchase Biogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
